FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Lillicrap

Research Profile

Chemicals & Drugs

Disorders

Physiology

Concepts & Ideas

Living Beings

Mouse
Dogs

Procedures

Co-author Network

Publications

TOP 3
C Rae; J St-Louis; C Demers; William Furlong; John Horsman; David Lillicrap; E Pullenayegum; Ronald Barr
Bleeding disorders, menorrhagia and iron deficiency: impacts on health-related quality of life.
Paula D James; David Lillicrap
The molecular characterization of von Willebrand disease: good in parts.
M Bowman; Christine Brown; M Deforest; P James; Jayne Leggo; David Lillicrap; Colleen Notley; Shawn Tinlin; A Tuttle; Victor S Blanchette
The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Lillicrap (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: C Rae; J St-Louis; C Demers; William Furlong; John Horsman; David Lillicrap; E Pullenayegum; Ronald Barr
Bleeding disorders, menorrhagia and iron deficiency: impacts on health-related quality of life.
Haemophilia : the official journal of the World Federation of Hemophilia 2013;19(3):385-91.
2013: Paula D James; David Lillicrap
The molecular characterization of von Willebrand disease: good in parts.
British journal of haematology 2013;161(2):166-76.
2013: M Bowman; Christine Brown; M Deforest; P James; Jayne Leggo; David Lillicrap; Colleen Notley; Shawn Tinlin; A Tuttle; Victor S Blanchette
The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles.
Journal of thrombosis and haemostasis : JTH 2013;11(3):512-20.
2013: M Golder; Jeffrey D Mewburn; David Lillicrap
In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process.
Thrombosis and haemostasis 2013;109(1):53-60.
2013: David Lillicrap
The future of hemostasis management.
Pediatric blood & cancer 2013;60 Suppl 1():S44-7.
2012: David Lillicrap
A complex substitute: antibody therapy for hemophilia.
Nature medicine 2012;18(10):1460-1.
2012: David Lillicrap
The World Federation of Hemophilia and research.
Haemophilia : the official journal of the World Federation of Hemophilia 2012;18 Suppl 4():24-7.
2012: Paula D James; David Lillicrap
von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.
American journal of hematology 2012;87 Suppl 1():S4-11.
2012: C M Pruss; A Bryant; M Golder; Sandra L Haberichter; Carol Hegadorn; David Lillicrap
Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W.
Journal of thrombosis and haemostasis : JTH 2012;10(5):940-50.
2012: Kathryn E Webert; Manuel Carcao; David Lillicrap; G E Rivard; J St-Louis; J Teitel; Irwin R Walker
Low prevalence of inhibitor antibodies in the Canadian haemophilia population.
Haemophilia : the official journal of the World Federation of Hemophilia 2012;18(3):e254-9.
2011: Madhu Gupta; David Lillicrap; Ann Marie Stain; Kenneth D Friedman; Manuel Carcao
Therapeutic consequences for misdiagnosis of type 2N von Willebrand disease.
Pediatric blood & cancer 2011;57(6):1081-3.
2011: J D Robertson; P R Yenson; V S Blanchette; M D Carcao; David Lillicrap; Colleen Notley; M L Rand; Paula D James
Expanded phenotype-genotype correlations in a pediatric population with type 1 von Willebrand disease.
Journal of thrombosis and haemostasis : JTH 2011;9(9):1752-60.
2011: Dorthe Viuff; T Saugstrup; Tw Barrowcliffe; M Ezban; David Lillicrap
International comparative field study of N8 evaluating factor VIII assay performance.
Haemophilia : the official journal of the World Federation of Hemophilia 2011;17(4):695-702.
2011: Cynthia M Pruss; Mia Golder; Andrea Bryant; Carol Hegadorn; Erin Burnett; Kimberly Laverty; Kate Sponagle; Aly Dhala; Colleen Notley; Sandra Haberichter; David Lillicrap
Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models.
Blood 2011;117(16):4358-66.
2011: Hideto Matsui; Carol Hegadorn; Margareth Ozelo; Erin Burnett; Angie Tuttle; Andrea Labelle; Paul B McCray; Luigi Naldini; Brian Brown; Christine Hough; David Lillicrap
A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.
Molecular therapy : the journal of the American Society of Gene Therapy 2011;19(4):723-30.
2011: M Qadura; B Waters; E Burnett; R Chegeni; Christine Hough; Maha Othman; David Lillicrap
Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice.
Haemophilia : the official journal of the World Federation of Hemophilia 2011;17(2):288-95.
2011: Rouzbeh Chegeni; Linda Vickars; Emmanuel J Favaloro; David Lillicrap; Maha Othman
Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease.
Thrombosis research 2011;127(2):161-6.
2011: Hanni Darwish; Gillianne Mundell; Dale Engen; David Lillicrap; Mariana Silva; Paula James
Early intraoperative blood collection does not affect complete blood counts, von Willebrand factor or factor VIII levels in normal children.
Journal of pediatric hematology/oncology 2011;33(1):47-9.
2010: Maha Othman; Yvette Chirinian; Christine Brown; Colleen Notley; Nicholas Hickson; Daniel Hampshire; Suzanne Buckley; Simon Waddington; Alan L Parker; Andrew Baker; Paula James; David Lillicrap
Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease.
Blood 2010;116(18):3645-52.
2010: Maha Othman; S Powell; W M Hopman; David Lillicrap
Variability of thromboelastographic responses following the administration of rFVIIa to haemophilia A dogs supports the individualization of therapy with a global test of haemostasis.
Haemophilia : the official journal of the World Federation of Hemophilia 2010;16(6):919-25.
2010: David Lillicrap
Improvements in factor concentrates.
Current opinion in hematology 2010;17(5):393-7.
2010: Ajit Thakur; Ruchira Sengupta; Hideto Matsui; David Lillicrap; Kim Jones; Gonzalo Hortelano
Characterization of viability and proliferation of alginate-poly-L-lysine-alginate encapsulated myoblasts using flow cytometry.
Journal of biomedical materials research. Part B, Applied biomaterials 2010;94(2):296-304.
2010: M Bowman; W M Hopman; Dilys Rapson; David Lillicrap; M Silva; P James
A prospective evaluation of the prevalence of symptomatic von Willebrand disease (VWD) in a pediatric primary care population.
Pediatric blood & cancer 2010;55(1):171-3.
2010: Mia Golder; Cynthia M Pruss; Carol Hegadorn; Jeffrey Mewburn; Kimberly Laverty; Kate Sponagle; David Lillicrap
Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions.
Blood 2010;115(23):4862-9.
2010: T T Biss; Victor S Blanchette; D S Clark; M Bowman; C D Wakefield; M Silva; David Lillicrap; P D James; Margaret L Rand
Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire.
Journal of thrombosis and haemostasis : JTH 2010;8(5):950-6.
2010: M Bowman; W M Hopman; Dilys Rapson; David Lillicrap; P James
The prevalence of symptomatic von Willebrand disease in primary care practice.
Journal of thrombosis and haemostasis : JTH 2010;8(1):213-6.
2010: Shoshana Revel-Vilk; Victor S Blanchette; Markus Schmugge; D S Clark; David Lillicrap; M L Rand
In vitro and in vivo stability of diluted recombinant factor VIII for continuous infusion use in haemophilia A.
Haemophilia : the official journal of the World Federation of Hemophilia 2010;16(1):72-9.
2009: A M Mullah-Ali; Anthony K C Chan; David Lillicrap; K Decker; W Seroski; K Moffat; Irwin Walker; M K Pai
Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia A.
Haemophilia : the official journal of the World Federation of Hemophilia 2009;15(6):1258-61.
2009: E Berber; Paula D James; Christine Hough; David Lillicrap
An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution.
Journal of thrombosis and haemostasis : JTH 2009;7(10):1672-9.
2009: B Waters; David Lillicrap
The molecular mechanisms of immunomodulation and tolerance induction to factor VIII.
Journal of thrombosis and haemostasis : JTH 2009;7(9):1446-56.
2009: Maha Othman; S Powell; Y Chirinian; Carol Hegadorn; W Hopman; David Lillicrap
Thromboelastography reflects global hemostatic variation among severe haemophilia A dogs at rest and following acute exercise.
Haemophilia : the official journal of the World Federation of Hemophilia 2009;15(5):1126-34.
2009: David Lillicrap; Guo-ping He; Jayne Leggo; Yu-sheng Liu; Xian-hong Tong; Gui-xiang Zhou; Li-hua Luo
[Application studies on the gene diagnosis and carrier detection of hemophilia A by using polymerase chain reaction-conformation sensitive gel electrophoresis].
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2009;26(4):393-9.
2009: Mohammad Qadura; Braden Waters; Erin Burnett; Rouzbeh Chegeni; Scott Bradshaw; Christine Hough; Maha Othman; David Lillicrap
Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
Blood 2009;114(4):871-80.
2009: Hideto Matsui; Masaru Shibata; Brian Brown; Andrea Labelle; Carol Hegadorn; Chandler Andrews; Marinee K L Chuah; Thierry VandenDriessche; Carol H Miao; Christine Hough; David Lillicrap
A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.
Blood 2009;114(3):677-85.
2009: David Lillicrap
Genotype/phenotype association in von Willebrand disease: is the glass half full or empty?
Journal of thrombosis and haemostasis : JTH 2009;7 Suppl 1():65-70.
2009: Braden Waters; Mohammad Qadura; Erin Burnett; Rouzbeh Chegeni; Andrea Labelle; Patrick Thompson; Christine Hough; David Lillicrap
Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response.
Blood 2009;113(1):193-203.
2008: Cynthia M Pruss; Colleen Notley; Carol A Hegadorn; Lee A O'Brien; David Lillicrap
ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor.
British journal of haematology 2008;143(4):552-8.
2008: Christine Hough; C L Cameron; Colleen Notley; Christine Brown; L O'Brien; A M Keightley; E Berber; David Lillicrap
Influence of a GT repeat element on shear stress responsiveness of the VWF gene promoter.
Journal of thrombosis and haemostasis : JTH 2008;6(7):1183-90.
2008: Jeremy Robertson; David Lillicrap; Paula D James
Von Willebrand disease.
Pediatric clinics of North America 2008;55(2):377-92, viii-ix.
2008: Srinivasa Prasad; David Lillicrap; Andrea Labelle; Sabine Knappe; Tracy Keller; Erin Burnett; Sandra Powell; Kirk W Johnson
Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.
Blood 2008;111(2):672-9.
2008: David Lillicrap
Extending half-life in coagulation factors: where do we stand?
Thrombosis research 2008;122 Suppl 4():S2-8.
2008: Pieter W Kamphuisen; David Lillicrap
Coagulation factors--molecular attributes and their clinical impact.
Thrombosis research 2008;122 Suppl 4():S1.
2008: J Stakiw; M Bowman; Carol Hegadorn; C Pruss; Colleen Notley; Evelyn Groot; Peter J Lenting; Dilys Rapson; David Lillicrap; P James
The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease.
Journal of thrombosis and haemostasis : JTH 2008;6(1):90-6.
2007: Hideto Matsui; Masaru Shibata; Brian Brown; Andrea Labelle; Carol Hegadorn; Chandler Andrews; Robert P Hebbel; Jacques Galipeau; Christine Hough; David Lillicrap
Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Stem cells (Dayton, Ohio) 2007;25(10):2660-9.
2007: Maha Othman; David Lillicrap
Distinguishing between non-identical twins: platelet type and type 2B von Willebrand disease.
British journal of haematology 2007;138(5):665-6.
2007: Paula D James; Colleen Notley; Carol Hegadorn; Man-Chiu Poon; I Walker; Dilys Rapson; David Lillicrap
Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study.
Journal of thrombosis and haemostasis : JTH 2007;5(9):1914-22.
2007: Glenn F Pierce; David Lillicrap; Steven W Pipe; Thierry VandenDriessche
Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment.
Journal of thrombosis and haemostasis : JTH 2007;5(5):901-6.
2007: Maha Othman; Andrea Labelle; Ian Mazzetti; Hisham S Elbatarny; David Lillicrap
Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.
Blood 2007;109(7):2832-9.
2007: C Barnes; Victor Blanchette; David Lillicrap; K Mann; Ann Marie Stain; Jayne Leggo; P Hilliard; Manuel Carcao
Different clinical phenotype in triplets with haemophilia A.
Haemophilia : the official journal of the World Federation of Hemophilia 2007;13(2):202-5.
2007: David Lillicrap
Von Willebrand disease - phenotype versus genotype: deficiency versus disease.
Thrombosis research 2007;120 Suppl 1():S11-6.
2007: Paula D James; Colleen Notley; Carol Hegadorn; Jayne Leggo; Angie Tuttle; Shawn Tinlin; Christine Brown; Chandler Andrews; Andrea Labelle; Yvette Chirinian; Lee O'Brien; Maha Othman; Georges-Etienne Rivard; Dilys Rapson; Christine Hough; David Lillicrap
The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.
Blood 2007;109(1):145-54.
2006: Fiona E M Rawle; K P Pratt; Andrea Labelle; Howard L Weiner; Christine Hough; David Lillicrap
Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain.
Journal of thrombosis and haemostasis : JTH 2006;4(10):2172-9.
2006: E Berber; Jayne Leggo; Christine Brown; E Berber; N Gallo; Harriet E Feilotter; David Lillicrap
DNA microarray analysis for the detection of mutations in hemophilia A.
Journal of thrombosis and haemostasis : JTH 2006;4(8):1756-62.
2006: Paula James; David Lillicrap
Genetic testing for von Willebrand disease: the Canadian experience.
Seminars in thrombosis and hemostasis 2006;32(5):546-52.
2006: David Lillicrap; S C Nair; A Srivastava; F Rodeghiero; I Pabinger; A B Federici
Laboratory issues in bleeding disorders.
Haemophilia : the official journal of the World Federation of Hemophilia 2006;12 Suppl 3():68-75.
2006: David Lillicrap; Thierry VandenDriessche; K High
Cellular and genetic therapies for haemophilia.
Haemophilia : the official journal of the World Federation of Hemophilia 2006;12 Suppl 3():36-41.
2006: Haiyan Jiang; David Lillicrap; Susannah Patarroyo-White; Tongyao Liu; Xiaobing Qian; Ciaran D Scallan; Sandra Powell; Tracey Keller; Morag McMurray; Andrea Labelle; Dea Nagy; Joseph Vargas; Shangzhen Zhou; Linda B Couto; Glenn F Pierce
Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
Blood 2006;108(1):107-15.
2006: Brian M Feldman; Mohan Pai; Georges-Etienne Rivard; S Israels; Man-Chiu Poon; C Demers; S Robinson; K-H Luke; J K M Wu; K Gill; David Lillicrap; Paul Babyn; Marjorie McLimont; Victor S Blanchette
Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.
Journal of thrombosis and haemostasis : JTH 2006;4(6):1228-36.
2006: Paula D James; A D Paterson; Colleen Notley; Cherie Cameron; Carol Hegadorn; Shawn Tinlin; Christine Brown; L O'Brien; Jayne Leggo; David Lillicrap
Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study.
Journal of thrombosis and haemostasis : JTH 2006;4(4):783-92.
2006: An Van Damme; Lieven Thorrez; Ling Ma; Herman H Vandenburgh; Jeroen Eyckmans; Francesco Dell'Accio; Cosimo De Bari; Frank P Luyten; David Lillicrap; Désiré Collen; Thierry VandenDriessche; Marinee K L Chuah
Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells.
Stem cells (Dayton, Ohio) 2006;24(4):896-907.
2006: K Roland; Dilys Rapson; David Lillicrap; P James
The value of genetic testing for type 2B Von Willebrand disease.
Clinical and laboratory haematology 2006;28(1):17-21.
2006: David Lillicrap
The role of immunomodulation in the management of factor VIII inhibitors.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2006;():421-5.
2005: Paula D James; Sanj Raut; Georges-Etienne Rivard; Man-Chiu Poon; Margaret Warner; Susan McKenna; Jayne Leggo; David Lillicrap
Aminoglycoside suppression of nonsense mutations in severe hemophilia.
Blood 2005;106(9):3043-8.
2005: Christine Hough; David Lillicrap
Gene therapy for hemophilia: an imperative to succeed.
Journal of thrombosis and haemostasis : JTH 2005;3(6):1195-205.
2005: Maha Othman; Colleen Notley; Frances Louise Lavender; Helen White; Christopher D Byrne; David Lillicrap; Denise Frances O'Shaughnessy
Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease.
Blood 2005;105(11):4330-6.
2005: Lee A O'Brien; Jeffrey J Sutherland; Donald F Weaver; David Lillicrap
Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations.
Journal of thrombosis and haemostasis : JTH 2005;3(4):796-7.
2005: Christine Hough; Carla Cuthbert; Colleen Notley; Christine Brown; Carol Hegadorn; Ergul Berber; David Lillicrap
Cell type-specific regulation of von Willebrand factor expression by the E4BP4 transcriptional repressor.
Blood 2005;105(4):1531-9.
2004: Fiona E M Rawle; Chang-Xin Shi; Brian Brown; Alexis McKinven; Shawn Tinlin; Frank L Graham; Christine Hough; David Lillicrap
Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
The journal of gene medicine 2004;6(12):1358-68.
2004: Paula D James; Lee A O'Brien; Carol Hegadorn; Colleen Notley; Gary D Sinclair; Christine Hough; Man-Chiu Poon; David Lillicrap
A novel type 2A von Willebrand factor mutation located at the last nucleotide of exon 26 (3538G>A) causes skipping of 2 nonadjacent exons.
Blood 2004;104(9):2739-45.
2004: Jeffrey J Sutherland; Lee A O'Brien; David Lillicrap; Donald F Weaver
Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations.
Journal of molecular modeling 2004;10(4):259-70.
2004: Iris Hedlund-Treutiger; Shoshana Revel-Vilk; Victor S Blanchette; Julie A Curtin; David Lillicrap; Margaret L Rand
Reliability and reproducibility of classification of children as "bleeders" versus "non-bleeders" using a questionnaire for significant mucocutaneous bleeding.
Journal of pediatric hematology/oncology 2004;26(8):488-91.
2004: Lee A O'Brien; Jeffrey J Sutherland; Carol Hegadorn; K Benford; H Racz; Dilys Rapson; Christine Hough; David Lillicrap
A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers.
Journal of thrombosis and haemostasis : JTH 2004;2(7):1135-42.
2004: Fiona E M Rawle; David Lillicrap
Preclinical animal models for hemophilia gene therapy: predictive value and limitations.
Seminars in thrombosis and hemostasis 2004;30(2):205-13.
2004: Jerome M Teitel; Dorothy Barnard; S Israels; David Lillicrap; Man-Chiu Poon; J Sek
Home management of haemophilia.
Haemophilia : the official journal of the World Federation of Hemophilia 2004;10(2):118-33.
2004: Brian D Brown; Chang-Xin Shi; Sandra Powell; David J Hurlbut; Frank L Graham; David Lillicrap
Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
Blood 2004;103(3):804-10.
2004: Brian D Brown; Chang-Xin Shi; Fiona E M Rawle; Shawn Tinlin; A McKinven; Christine Hough; Frank L Graham; David Lillicrap
Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice.
Journal of thrombosis and haemostasis : JTH 2004;2(1):111-8.
2003: Ciaran D Scallan; David Lillicrap; Haiyan Jiang; Xiaobing Qian; Susannah Patarroyo-White; Amy E Parker; Tongyao Liu; Joseph Vargas; Dea Nagy; Sharon K Powell; J Fraser Wright; Patricia V Turner; Shawn Tinlin; Sandra E Webster; Alan McClelland; Linda B Couto
Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.
Blood 2003;102(6):2031-7.
2003: Lee A O'Brien; Paula D James; Maha Othman; Ergul Berber; Cherie Cameron; Colleen Notley; Carol Hegadorn; Jeffrey J Sutherland; Christine Hough; Georges-Etienne Rivard; Denise O'Shaunessey; David Lillicrap
Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease.
Blood 2003;102(2):549-57.
2003: Anjali Sharathkumar; David Lillicrap; Victor S Blanchette; Melissa Kern; Jayne Leggo; Ann Marie Stain; LA Brooker; Manuel Carcao
Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.
Journal of thrombosis and haemostasis : JTH 2003;1(6):1228-36.
2003: Marinee K L Chuah; Gudrun Schiedner; Lieven Thorrez; Brian Brown; Marion Johnston; Veerle Gillijns; Sabine Hertel; Nico van Rooijen; David Lillicrap; Désiré Collen; Thierry VandenDriessche; Stefan Kochanek
Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Blood 2003;101(5):1734-43.
2002: Jennifer Oakes; Philip M Hahn; David Lillicrap; Robert L Reid
A survey of recommendations by gynecologists in Canada regarding oral contraceptive use in the perioperative period.
American journal of obstetrics and gynecology 2002;187(6):1539-43.
2002: Colleen Notley; Annie Killoran; Cherie Cameron; Kimberly Wynd; Christine Hough; David Lillicrap
The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo.
Human gene therapy 2002;13(13):1583-93.
2002: Brian D Brown; David Lillicrap
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
Blood 2002;100(4):1133-40.
2002: David Lillicrap
Gene expression: overview and clinical implications.
Vox sanguinis 2002;83 Suppl 1():77-9.
2002: Bert Verbruggen; Waander L van Heerde; Irena Novákovà; David Lillicrap; Alan Giles
A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay.
Thrombosis and haemostasis 2002;88(2):362-4.
2002: Christine Hough; Seiki Kamisue; Cherie Cameron; Colleen Notley; Shawn Tinlin; Alan Giles; David Lillicrap
Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia.
Thrombosis and haemostasis 2002;87(4):659-65.
2002: Man-Chiu Poon; David Lillicrap; Caroline Hensman; Robert Card; Mary-Frances Scully
Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study.
Thrombosis and haemostasis 2002;87(3):431-5.
2002: David Lillicrap; Man-Chiu Poon; I Walker; F Xie; B A Schwartz
Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
Thrombosis and haemostasis 2002;87(2):224-30.
2002: Y G Xie; H Zheng; Jayne Leggo; M F Scully; David Lillicrap
A founder factor VIII mutation, valine 2016 to alanine, in a population with an extraordinarily high prevalence of mild hemophilia A.
Thrombosis and haemostasis 2002;87(1):178-9.
2001: Rosa Di Bitondo; C L Cameron; Martina E Daly; SA Croft; RP Steeds; Kevin S Channer; NJ Samani; David Lillicrap; Peter R Winship
The -1185 A/G and -1051 G/A dimorphisms in the von Willebrand factor gene promoter and risk of myocardial infarction.
British journal of haematology 2001;115(3):701-6.
2001: AM Gallo-Penn; Pamela S Shirley; Julie L Andrews; Shawn Tinlin; S Webster; Cherie Cameron; Christine Hough; Colleen Notley; David Lillicrap; Michael Kaleko; Sheila Connelly
Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.
Blood 2001;97(1):107-13.
2000: David Lillicrap
Hemophilia treatment. Gene therapy, factor VIII antibodies and immune tolerance: hopes and concerns.
Haematologica 2000;85(10 Suppl):108-11; discussion 111-2.
2000: JA Dean; Victor S Blanchette; Manuel Carcao; Ann Marie Stain; Cathy Sparling; Jürgen Siekmann; Peter L Turecek; David Lillicrap; Margaret L Rand
von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
Thrombosis and haemostasis 2000;84(3):401-9.
2000: M Begbie; Colleen Notley; Shawn Tinlin; L Sawyer; David Lillicrap
The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP.
Thrombosis and haemostasis 2000;84(2):216-22.
2000: P J Harvey; A M Keightley; YM Lam; Cherie Cameron; David Lillicrap
A single nucleotide polymorphism at nucleotide -1793 in the von Willebrand factor (VWF) regulatory region is associated with plasma VWF:Ag levels.
British journal of haematology 2000;109(2):349-53.
2000: D H Lee; Irwin R Walker; Jerome M Teitel; Man-Chiu Poon; B Ritchie; J Akabutu; Gary D Sinclair; Mohan Pai; J W Wu; S Reddy; C Carter; G Growe; David Lillicrap; M Lam; Morris A Blajchman
Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A.
Thrombosis and haemostasis 2000;83(3):387-91.
1999: David Lillicrap
Molecular diagnosis of inherited bleeding disorders and thrombophilia.
Seminars in hematology 1999;36(4):340-51.
1999: Theodore E Warkentin; W M Sikov; David Lillicrap
Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia.
American journal of hematology 1999;62(1):44-8.
1999: AM Gallo-Penn; Pamela S Shirley; Julie L Andrews; Dawn B Kayda; Anne Pinkstaff; Michele Kaloss; Shawn Tinlin; Cherie Cameron; Colleen Notley; Christine Hough; David Lillicrap; Michael Kaleko; Sheila Connelly
In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.
Human gene therapy 1999;10(11):1791-802.
1999: A M Keightley; YM Lam; J N Brady; C L Cameron; David Lillicrap
Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter.
Blood 1999;93(12):4277-83.
1999: M Begbie; C Mueller; David Lillicrap
Enhanced binding of HLF/DBP heterodimers represents one mechanism of PAR protein transactivation of the factor VIII and factor IX genes.
DNA and cell biology 1999;18(2):165-73.
1998: Gabrielle DeVeber; Paul Monagle; A Chan; D MacGregor; R Curtis; S Lee; Patricia Vegh; Margaret Adams; Velma Marzinotto; MT Leaker; M Patricia Massicotte; David Lillicrap; Maureen Andrew
Prothrombotic disorders in infants and children with cerebral thromboembolism.
Archives of neurology 1998;55(12):1539-43.
1998: Y G Xie; David Lillicrap; S A Taylor
An association between the common hereditary hemochromatosis mutation and the factor V Leiden allele in a population with thrombosis.
Blood 1998;92(4):1461-2.
1998: David Lillicrap
The molecular basis of haemophilia B.
Haemophilia : the official journal of the World Federation of Hemophilia 1998;4(4):350-7.
1998: J N Brady; Colleen Notley; Cherie Cameron; David Lillicrap
Androgen effects on factor IX expression: in-vitro and in-vivo studies in mice.
British journal of haematology 1998;101(2):273-9.
1998: Cherie Cameron; Colleen Notley; S Hoyle; L McGlynn; Christine Hough; Seiki Kamisue; Alan Giles; David Lillicrap
The canine factor VIII cDNA and 5' flanking sequence.
Thrombosis and haemostasis 1998;79(2):317-22.
1996: L K McGlynn; Christopher R Mueller; M Begbie; Colleen Notley; David Lillicrap
Role of the liver-enriched transcription factor hepatocyte nuclear factor 1 in transcriptional regulation of the factor V111 gene.
Molecular and cellular biology 1996;16(5):1936-45.
1996: L M Boccia; David Lillicrap; K Newcombe; Christopher R Mueller
Binding of the Ets factor GA-binding protein to an upstream site in the factor IX promoter is a critical event in transactivation.
Molecular and cellular biology 1996;16(5):1929-35.
1996: EW Murray; David Lillicrap
von Willebrand disease: pathogenesis, classification, and management.
Transfusion medicine reviews 1996;10(2):93-110.
1995: Stylianos Antonarakis; Judith P. Rossiter; M Young; J Horst; P de Moerloose; S S Sommer; Rhett P Ketterling; Haig Kazazian ; Claude Négrier; Christine Vinciguerra; Jane Gitschier; Michel Goossens; Emmanuelle Girodon; N Ghanem; F Plassa; Jean-Maurice Lavergne; M Vidaud; J M Costa; Yves Laurian; S W Lin; S R Lin; M C Shen; David Lillicrap; S A Taylor; S Windsor; Sophie Valleix; Khedoudja Nafa; Y Sultan; Marc Delpech; C L Vnencak-Jones; J A Phillips; R C Ljung; E Koumbarelis; AE Gialeraki; Titika Mandalaki; P Vincent Jenkins; P W Collins; K John Pasi; Anne C Goodeve; Ian R Peake; F Eric Preston; Marianne Schwartz; E Scheibel; Jørgen Ingerslev; D N Cooper; D S Millar; V V Kakkar; F Giannelli; J A Naylor; E F Tizzano; Montserrat Baiget; M Domenech; Carme Altisent; J Tusell; M Beneyto; J I Lorenzo; Christine Gaucher; Claudine Mazurier; Kathelijne Peerlinck; Gert Matthijs; J J Cassiman; J Vermylen; Pier Giorgio Mori; M Acquila; Daniela Caprino; H Inaba
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study.
Blood 1995;86(6):2206-12.
1995: S Windsor; A Lyng; S A Taylor; B M Ewenstein; E J Neufeld; David Lillicrap
Severe haemophilia A in a female resulting from two de novo factor VIII mutations.
British journal of haematology 1995;90(4):906-9.
1995: Nigel Wood; G R Standen; EW Murray; David Lillicrap; L Holmberg; I R Peake; Jeffrey Bidwell
Rapid genotype analysis in type 2B von Willebrand's disease using a universal heteroduplex generator.
British journal of haematology 1995;89(1):152-6.
1994: D J Picketts; Christopher R Mueller; David Lillicrap
Transcriptional control of the factor IX gene: analysis of five cis-acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations.
Blood 1994;84(9):2992-3000.
1994: S Windsor; S A Taylor; David Lillicrap
Direct detection of a common inversion mutation in the genetic diagnosis of severe hemophilia A.
Blood 1994;84(7):2202-5.
1994: S Windsor; S A Taylor; David Lillicrap
Multiplex analysis of two intragenic microsatellite repeat polymorphisms in the genetic diagnosis of haemophilia A.
British journal of haematology 1994;86(4):810-5.
1993: F C Ling; C E Clarke; W E Corbett; David Lillicrap
Sensitivity of PCR in detecting monoclonal B cell proliferations.
Journal of clinical pathology 1993;46(7):624-7.
1993: P Lopez; D G Morris; P R Galbraith; David Lillicrap; H F Pross
Lymphoproliferative disease of "LAK cell" precursor large granular lymphocytes in association with celiac disease.
American journal of hematology 1993;43(2):116-22.
1993: D J Picketts; David Lillicrap; Christopher R Mueller
Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutation.
Nature genetics 1993;3(2):175-9.
1992: F C Ling; C E Clarke; David Lillicrap
Positive immunoglobulin gene rearrangement study by the polymerase chain reaction in a colonic adenocarcinoma.
American journal of clinical pathology 1992;98(1):116-9.
1992: D J Picketts; Cherie Cameron; S A Taylor; K V Deugau; David Lillicrap
Differential termination of primer extension: a novel, quantifiable method for detection of point mutations.
Human genetics 1992;89(2):155-7.
1992: S A Taylor; J Duffin; Cherie Cameron; Jerome M Teitel; B Garvey; David Lillicrap
Characterization of the original Christmas disease mutation (cysteine 206----serine): from clinical recognition to molecular pathogenesis.
Thrombosis and haemostasis 1992;67(1):63-5.
1992: D J Picketts; C D'Souza; P J Bridge; David Lillicrap
An A to T transversion at position -5 of the factor IX promoter results in hemophilia B.
Genomics 1992;12(1):161-3.
1992: EW Murray; Alan Giles; David Lillicrap
Germ-line mosaicism for a valine-to-methionine substitution at residue 553 in the glycoprotein Ib-binding domain of von Willebrand factor, causing type IIB von Willebrand disease.
American journal of human genetics 1992;50(1):199-207.
1992: G E Graham; P M MacLeod; David Lillicrap; P J Bridge
Gonadal mosaicism in a family with adrenoleukodystrophy: molecular diagnosis of carrier status among daughters of a gonadal mosaic when direct detection of the mutation is not possible.
Journal of inherited metabolic disease 1992;15(1):68-74.
1991: David Lillicrap; EW Murray; K Benford; V S Blanchette; G E Rivard; R Wensley; Alan Giles
Recurring mutations at CpG dinucleotides in the region of the von Willebrand factor gene encoding the glycoprotein Ib binding domain, in patients with type IIB von Willebrand's disease.
British journal of haematology 1991;79(4):612-7.
1991: David Lillicrap
The molecular pathology of hemophilia A.
Transfusion medicine reviews 1991;5(3):196-206.
1991: EW Murray; Alan Giles; P J Bridge; I R Peake; David Lillicrap
Cosegregation of von Willebrand factor gene polymorphisms and possible germinal mosaicism in type IIB von Willebrand disease.
Blood 1991;77(7):1476-83.
1991: P J Bridge; P M MacLeod; David Lillicrap
Carrier detection and prenatal diagnosis of Pelizaeus-Merzbacher disease using a combination of anonymous DNA polymorphisms and the proteolipid protein (PLP) gene cDNA.
American journal of medical genetics 1991;38(4):616-21.
1991: S A Taylor; K V Deugau; David Lillicrap
Somatic mosaicism and female-to-female transmission in a kindred with hemophilia B (factor IX deficiency).
Proceedings of the National Academy of Sciences of the United States of America 1991;88(1):39-42.
1991: L Shepherd; Cherie Cameron; P Galbraith; S Windsor; David Lillicrap
Absence of allelic loss on chromosome 5q by RFLP analysis in preleukemia.
Leukemia research 1991;15(5):297-303.
1990: D D Koeberl; C D Bottema; Rhett P Ketterling; P J Bridge; David Lillicrap; Steve S Sommer
Mutations causing hemophilia B: direct estimate of the underlying rates of spontaneous germ-line transitions, transversions, and deletions in a human gene.
American journal of human genetics 1990;47(2):202-17.
1990: S A Taylor; M B Liddell; I R Peake; A L Bloom; David Lillicrap
A mutation adjacent to the beta cleavage site of factor IX (valine 182 to leucine) results in mild haemophilia Bm.
British journal of haematology 1990;75(2):217-21.
1990: C D Bottema; D D Koeberl; Rhett P Ketterling; E J Bowie; S A Taylor; David Lillicrap; Amy D Shapiro; G Gilchrist; Steve S Sommer
A past mutation at isoleucine 397 is now a common cause of moderate/mild haemophilia B.
British journal of haematology 1990;75(2):212-6.
1990: David Lillicrap; M Pinto; K Benford; P M Ford; S Ford
Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines.
American journal of clinical pathology 1990;93(6):771-5.
1990: P M Ford; D Brunet; David Lillicrap; SE Ford
Premature stroke in a family with lupus anticoagulant and antiphospholipid antibodies.
Stroke; a journal of cerebral circulation 1990;21(1):66-71.
1990: David Lillicrap; P J Bridge; Alan Giles
Organization of a hemophilia genetic screening program. Ontario Hemophilia Study Group.
Progress in clinical and biological research 1990;324():19-28.
1990: David Lillicrap; S A Taylor; P C Schuringa; V S Blanchette; J K Lovsted; L J Weiler; P J Bridge
Variation of the non-factor VIII sequences detected by a probe from intron 22 of the factor VIII gene.
Blood 1990;75(1):139-43.
1989: J Drouin; David Lillicrap; C A Izaguirre; M Sutherland; S Windsor; K Benford; H Hoogendorn; Alan Giles
Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis.
American journal of clinical pathology 1989;92(4):471-8.
1989: S A Taylor; P J Bridge; David Lillicrap
A BstXI polymorphism detected by the factor VIII genomic probe p.482.6 (F8C).
Nucleic acids research 1989;17(15):6426.
1989: M B Liddell; I R Peake; S A Taylor; David Lillicrap; J C Giddings; A L Bloom
Factor IX Cardiff: a variant factor IX protein that shows abnormal activation is caused by an arginine to cysteine substitution at position 145.
British journal of haematology 1989;72(4):556-60.
1989: M B Liddell; David Lillicrap; I R Peake; A L Bloom
Defective propeptide processing and abnormal activation underlie the molecular pathology of factor IX Troed-y-Rhiw.
British journal of haematology 1989;72(2):208-15.
1989: P J Bridge; David Lillicrap
Molecular diagnosis of the fragile X [Fra (X)] syndrome: calculation of risks based on flanking DNA markers in small phase-unknown families.
American journal of medical genetics 1989;33(1):92-9.
1989: SE Ford; David Lillicrap; D Brunet; P Ford
Thrombotic endocarditis and lupus anticoagulant. A pathogenetic possibility for idiopathic 'rheumatic type' valvular heart disease.
Archives of pathology & laboratory medicine 1989;113(4):350-3.
1988: M J Hogan; D G Brunet; P M Ford; David Lillicrap
Lupus anticoagulant, antiphospholipid antibodies and migraine.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1988;15(4):420-5.
1988: David Lillicrap; Jeanette J A Holden; Alan Giles; Bradley N White
Carrier detection strategy in haemophilia A: the benefits of combined DNA marker analysis and coagulation testing in sporadic haemophilic families.
British journal of haematology 1988;70(3):321-6.
1988: S A Taylor; David Lillicrap; Victor Blanchette; Alan Giles; Jeanette J A Holden; Bradley N White
A complete deletion of the factor IX gene and new TaqI variant in a hemophilia B kindred.
Human genetics 1988;79(3):273-6.
1988: P M Ford; SE Ford; David Lillicrap
Association of lupus anticoagulant with severe valvular heart disease in systemic lupus erythematosus.
The Journal of rheumatology 1988;15(4):597-600.
1987: David Lillicrap; Bradley N White; Jeanette J A Holden; Alan Giles
Carrier detection in the hemophilias.
American journal of hematology 1987;26(3):285-96.
1987: H Grover; M A Phillips; David Lillicrap; Alan Giles; M Bernadette Garvey; Jerome M Teitel; Georges-Etienne Rivard; Victor Blanchette; Bradley N White; Jeanette J A Holden
Carrier detection of haemophilia A using DNA markers in families with an isolated affected male.
Clinical genetics 1987;32(1):10-9.
1987: David Lillicrap; W E Corbett; Alan Giles; A D Ginsburg
Erythroblast multinuclearity in bone marrow and spleen. Congenital dyserythropoietic anemia-like abnormalities without functional evidence of dyserythropoiesis.
Archives of pathology & laboratory medicine 1987;111(6):536-9.
1986: David Lillicrap; M B Liddell; R J Matthews; I R Peake; A L Bloom
Comparison of phenotypic assessment and the use of two restriction fragment length polymorphisms in the diagnosis of the carrier state in haemophilia B.
British journal of haematology 1986;62(3):557-65.
1985: I R Peake; David Lillicrap; M B Liddell; R J Matthews; A L Bloom
Linked and intragenic probes for haemophilia A.
Lancet 1985;2(8462):1003-4.